The present invention relates generally to systems and methods for small molecule exchange with a fluid, preferably for gas exchange with a physiological fluid, and more preferably for oxygenating and removing carbon dioxide from a physiologic fluid.
The main function of lungs is to transfer oxygen from the atmosphere into the blood and expel carbon dioxide therefrom to the atmosphere. For patients with diseased or damaged lungs, this exchange of gas is compromised and there are few treatment options. Some of the most common diseases leading to end-stage lung failure include, inter alia, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), and pulmonary hypertension (PH). There are also many people suffering from lung cancer and poor lung function due to years of smoking who are not eligible for a lung resection or lung transplantation.
Lung transplantation remains the main therapy for chronic irreversible respiratory failure. However, lung transplantation is not very common; only about 2,000 procedures are performed each year in the United States. The most common indications for lung transplantation include COPD, CF, IPF, and PH. Patients with lung cancer are not candidates for transplantation because the use of immunosuppression could potentially cause the cancer to spread. Lung transplant candidates can die waiting for an organ donor since the average waiting time period may exceed two years. The overall results are not ideal due to the extensive surgery required, deterioration of the patient's condition during the waiting period, the complications of chronic immunosuppression, infection, and the development of chronic rejection. Also, many patients with chronic lung disease tend to be older individuals who are poor candidates for transplantation because they do not tolerate immunosuppression.
Another option for patients suffering from diseased or damaged lungs may be to utilize an enriched oxygen supply, frequently in conjunction with a ventilator. However, this has been shown to create dependency and a host of other ventilator-related disorders.
The concept of using an artificial lung in clinical medicine to take over the gas exchange function of diseased or damaged lung(s) dates back to the development of the heart-lung machine in 1954. Cardiopulmonary bypass (CPB) is a technique used to take over the function of the heart and lungs during surgery by regulating the circulation of blood and oxygen within a person's body. The artificial lung may provide short-term pulmonary support during extensive operations on the heart.
Over the last few decades, several conventional mechanical-assisting devices have been developed to treat diseased or damaged lung(s) acute reversible respiratory failure due to acute respiratory distress syndrome (ARDS). Conventional systems have also been developed for short-term pulmonary support (e.g., days to a few weeks). These systems include extracorporeal membrane oxygenation (ECMO) devices, extracorporeal carbon dioxide removal (ECCO2R) devices, and intravascular oxygenators (IVOX) devices.
Although conventional ECMO and IVOX systems have been used for aiding patients with diseased or damaged lung(s), they are both one-stage systems with distinct drawbacks. ECMO devices produce significant complication rates and typically do not provide a significant improvement. IVOX devices may alleviate some of the problems associated with ECMO devices. However, the gas exchange area of IVOX devices may be too small and the device may not provide the needed total support for gas exchange. Also, IVOX devices may not take away excess carbon dioxide leftover within the system. Finally, conventional one-stage IVOX systems typically include membranous or fibrous components used for oxygenation. Typically, a bundle of hollow fibers may be used as the oxygenating element. Exposing blood to the large artificial surface area needed for gas exchange often causes blood activation and thrombogenesis. ECCO2R and ECMO are also one-stage systems and may be limited by the inclusion of fibers that come in contact with blood thereby causing blood activation and thrombogenesis.
Generally, these devices use a membrane that can selectively allow the transport of gas molecules. Unfortunately, the interaction of the blood with the membrane results in the blood laying down a protein layer on the membrane in the start of the blood's coagulation cascade. The protein layer renders the membrane less efficient to the gas transport. As coagulation progresses further, the device becomes less effective and greater pressures are required to pump the blood through the device, eventually reaching the point where blood cells lyse as they are pumped to and through the device, creating further problems.
There are advances that can be applied to materials that would decrease or even eliminate these issues. However, the membrane material poses the key problem in these devices because it has proven difficult to apply these advances to a gas permeable surface while maintaining efficiency of gas transfer.
There has also been some research in utilizing an oxygen-carrying liquid to bring oxygen directly to the blood, however this research has focused on using small bubbles of liquid that are injected into the blood and then removed using a selective filter. When bubbles of fluid are injected into the blood, the system typically requires a means for pulling the bubbles out of the blood before it flows back into a user, which may also cause blood activation. These systems typically do not appreciably decrease the amount of carbon dioxide in the blood.
One aspect of the disclosure relates to an apparatus for exchanging small molecules with a fluid. The apparatus includes a small-molecule conduit for providing a first fluid having a first type of small molecule, a target fluid conduit for providing a target fluid having a second type of small molecule therein, and a carrier fluid conduit for providing a carrier fluid that is configured to at least one of: (i) receive at least some of the first type of small molecule from the first fluid and transfer at least some of the first type of small molecule to the target fluid and (ii) receive at least some of the second type of small molecule from the target fluid and transfer at least some of the second type of small molecule to the first fluid. The apparatus further includes an exchange module having an exchange chamber in fluid communication with the small-molecule conduit, the target fluid conduit and the carrier fluid conduit to receive the first fluid, the carrier fluid, and the target fluid with the exchange chamber, wherein the exchange chamber is configured (i) to position the first fluid relative to the carrier fluid to permit the transfer of at least one of the first type of small molecule and the second type of small molecule between the first fluid and the carrier fluid and (ii) to position the carrier fluid relative to the target fluid to permit the transfer of at least one of the first type of small molecule and the second type of small molecule between the target fluid and the carrier fluid.
Another aspect of the disclosure relates to a method of exchanging small molecules with a fluid. The method includes flowing, through an exchange chamber of an exchange module on a first side of a membrane, a first fluid comprising a first type of small molecules, flowing, through the exchange chamber of the exchange module on a second side of the membrane, a target fluid having a second type of small molecules therein, and flowing, through the exchange chamber of the exchange module on the second side of the membrane and between the target fluid and the membrane, a carrier fluid that at least one of: (i) receives through the membrane at least some of the first type of small molecules from the first fluid and transfers at least some of the first type of small molecules to the target fluid and (ii) receives at least some of the second type of small molecules from the target fluid and transfers through the membrane at least some of the second type of small molecules to the first fluid. The first fluid, the target fluid, and the carrier fluid are flowed simultaneously through the exchange chamber of the exchange module.
Another aspect of the disclosure relates to a method of exchanging small molecules with a fluid. The method includes providing a primary exchange module configured to: receive a first fluid having a first type of small molecule therein; receive a carrier fluid having second type of small molecule therein, and transfer at least one of: (i) the first type of small molecule from the first fluid to the carrier fluid and (ii) the second type of small molecule from the carrier fluid to the first fluid to create at least one of a carrier fluid loaded with the first type of small molecule and a first fluid loaded with the second type of small molecule. The method further includes providing a secondary exchange module configured to: receive the carrier fluid loaded with the first type of small molecule; receive a target fluid having the second type of small molecule therein; and transfer at least one of: (i) the first type of small molecule from the carrier fluid loaded with the first type of small molecule to the target fluid and (ii) the second type of small molecule from the target fluid to the carrier fluid to create at least one of a target fluid loaded with the first type of small molecule and a carrier fluid loaded with the second type of small molecule. The method further includes implanting the secondary exchange module within a body of a patient, and positioning the primary exchange module external to the body of the patient.
Described herein are various systems and methods for exchanging small molecules with a fluid. In one embodiment, a two-stage system utilizes first and second exchange modules. In another embodiment, a single-stage system is provided by a single exchange module.
For ease of reference, embodiments in the present disclosure are described specifically with respect to oxygenating and removing carbon dioxide from a physiological fluid. However, it is to be understood that the systems and methods described herein apply to and can be used for other applications for exchanging small molecules with a fluid. Other potential applications to this system include hemodialysis, ultrafiltration, plasmapheresis, and the removal of bacteria from the blood stream. While the present application describes a gas having oxygen as a first fluid, a physiological fluid (such as blood) as a target fluid, and a carrier fluid that serves as an intermediary fluid, and it is to be understood that the systems and methods can be also used for other fluids. For example, in hemodialysis, the first fluid can be the dialysate, the carrier fluid can be plasma, and the target fluid can be blood. In ultrafiltration, the first fluid can be a liquid or a gas, the carrier fluid can be plasma or another liquid, and the target fluid can be blood. In plasmapheresis, the first fluid can be a liquid specially formulated to remove toxins, the carrier fluid can be plasma, and the target fluid can be blood.
Also for ease of reference, in the embodiments described herein, a two-way transfer of small molecules is described, particularly, delivering oxygen to and removing carbon dioxide from a physiological fluid. It is to be understood, however, that systems described herein can also be configured to accommodate one-way transfer alone, such as providing oxygen to the physiological fluid or removing carbon dioxide from the physiological fluid. In such embodiments, the small molecules of the first fluid are transferred to the carrier fluid and then to the target fluid, or the small molecules are transferred from the target fluid to the carrier fluid and then to the first fluid. As a further example, in hemodialysis, the target fluid (blood) may transfer waste products to the dialysate. Other such configurations are envisioned for one-way or two-way transfer in various applications.
Referring to
As shown in
System 10 also includes secondary exchange module 20 which receives the carrier fluid and a target fluid (i.e., a fluid that is the target for the small molecule exchange), for example, oxygen loaded carrier fluid 18 from primary exchange module 12, indicated at 19, and physiological fluid 22 having carbon dioxide therein indicated at 23. Physiological fluid 22 may include blood, serum, or any similar type physiological fluid having carbon dioxide therein. In one example, physiological fluid 22 having carbon dioxide therein may be received from vascular system of a patient 120. Secondary exchange module transfers the oxygen from oxygen loaded carrier fluid 18 to physiological fluid 22 and transfers carbon dioxide from physiological fluid 22 to produce oxygen loaded physiological fluid 24 and carrier fluid 16 having carbon dioxide therein. Oxygen loaded physiological fluid 24, which now has carbon dioxide removed, may then be transferred to vascular system of a patient 120, as shown at 121. Carrier fluid 16, having carbon dioxide therein, is transferred to primary exchange module 12, as shown at 130.
The result is system 10 receives physiological fluid 22 having carbon dioxide therein, effectively removes carbon dioxide therefrom and loads physiological fluid 22 with oxygen. Oxygen loaded physiological fluid 24 may be then transferred to vascular system of patient 120. Thus, system 10 can be used to effectively assist or replace the function of diseased or damaged lung(s) discussed in the Background section above. In one embodiment, system 10 may be used as an artificial lung.
Primary exchange module 12 preferably includes at least one array, e.g., array 25, shown in
Primary exchange module 12 may include a plurality of arrays 25. Each of arrays similarly includes hollow fibers 26 as discussed above. In this example, carrier fluid 16 having carbon dioxide therein enters primary exchange module 12 and then flows in between the plurality of arrays. Carrier fluid 16 then travels in an upward and downward direction into the arrays and flows in between and about hollow fibers 26 of the arrays. When carrier fluid 16 travels in between, about, and in close proximity to, hollow fibers 26, hollow fibers 26 efficiently transfer the oxygen in gas 14 to carrier fluid 16 and transfer the carbon dioxide in carrier fluid 16 to the gas inside hollow fibers 26 to create oxygen loaded carrier fluid 18 and carbon dioxide loaded gas 28, as depicted in
In one embodiment, the distance between one or more, or each of, hollow fibers 26 is preferably configured to provide the efficient transfer of the oxygen from the gas having oxygen therein to the carrier fluid and the transfer of the carbon dioxide from the carrier fluid to the gas as discussed above. In one example, the distance between one or more, or of each hollow fiber 26 is preferably smaller than or equal to the outer diameter hollow fibers 26. In one example, the distance between the hollow fibers 26 is about 100 microns and outer diameter distances of the hollow fibers are about 125 microns.
Referring now to secondary exchange module 20, the secondary exchange module 20 preferably includes at least one microfluidic channel 70, as shown in
In one example, channel 70 shown in
In one design, secondary exchange module 20 includes a plurality of channels, e.g., channels 70, 80, and 82 of
Referring to
Similarly, oxygen loaded carrier fluid 18 may flow into microtubule 87, enter channels 80, 82 at inlet plenums 140, 160, respectively, and then flows in the direction shown by arrows 148, 164 to the far end of channels 80, 82 where it exits channels 80, 82 as carrier fluid 16 having carbon dioxide therein via outlet plenums 150, 166, respectively. Carrier fluid 16 having carbon dioxide therein then flows into microtubule 96, travels down microtubule 96, and exits secondary exchange module 20 via outlet 97. Carrier fluid 16 having carbon dioxide therein may be then transferred to primary exchange module 12 (shown in
As shown in
In one embodiment, microfluidic channel 70, shown in
Preferably, carrier fluid 18 and physiological fluid 22 are immiscible with each other to stabilize and further separate the parallel flow thereof. Microfluidic channel 70 with opposing surfaces and/or microfluidic channels 80, 82 (which similarly have opposing surfaces) preferably includes a predetermined shape which increases the surface area thereof in relation to the cross-sectional area of the microfluidic channel to stabilize and further separate the parallel flow of carrier fluid 18 and physiological fluid 22. For example, channel 70 and/or channels 82, 82 may have a scalloped shape, a circular shape, an offset circular shape, or a rectangular shape. Other shapes that increase surface area relative to cross-sectional area will be known to those skilled in the art.
Preferably, microfluidic channel 70 and/or microfluidic channels 80, 82 are made of a bio-compatible material, such as polycarbonate, polyetherimide or similar type materials. In one design, carrier fluid 16 having carbon dioxide therein and/or oxygen loaded carrier fluid 18 may include a perfluorocarbon that prevents carrier fluid 16 from mixing with physiological fluid 22 having carbon dioxide therein.
One embodiment of system 10 is shown in
The housing 30 also can support structure for supplying fluids to the fluid channel 21. For example, a carrier fluid input 22A and a target fluid input 22B can be in fluid communication with an input channel 24A and an input channel 24B, respectively. In turn, the input channel 24A and the input channel 24B are in fluid communication with the fluid channel 21.
Each of inputs 22A and 22B can be configured, by conventional means, for connection with a respective fluid source (not shown) (e.g., an IV bag, etc.), such that fluid inputs 22A and 22B receive a carrier fluid and a target fluid, respectively, from the fluid sources. As shown in
The housing 30 also can support structure for receiving fluids from the fluid channel 21. For example, an output channel 25A and an output channel 25B are in fluid communication with the fluid channel 21. In turn, the output channel 25A and the output channel 25B are in fluid communication with a carrier fluid output 23A and a target fluid output 23B. Output channels 25A and 25B receive respective fluids from the fluid channel 21. The output channels 25A and 25B provide the respective fluids to the carrier fluid output 23A and the target fluid output 23B, respectively. Fluid outputs 23A and 23B are configured to exit a fluid flowing out of the apparatus, for example, a carrier fluid loaded with a type of small molecule transferred from the target fluid and a target fluid loaded with a type of small molecule transferred from the carrier fluid. The fluid outputs 23A and 23B can be configured, by conventional means, for connection with further tubing or other receptacles for the fluids.
Preferably, the housing 30 supports the fluid channel 21 such that fluid can be pumped to flow through the fluid channel such that the system (and specifically the fluid flow) is unaffected by gravity. The fluid channel 21 is configured to allow flow of multiple fluids (e.g., a carrier fluid and a target fluid) while substantially maintaining fluid separation. Thus, molecular transport can be facilitated between the two fluids without fluid intermixture occurring.
The fluid channel 21 can be formed in a variety of configurations. For example, it can be a flexible or rigid channel. Additionally, it can have a variety of cross-sectional shapes, but a rectangular cross-sectional shape with four sides is preferred. The fluid channel 21 can be formed of any suitable material for transporting biomaterials.
In some embodiments, the at least one first internal surface 31 has an affinity to the carrier fluid, and the at least one second internal surface 32 has an affinity to the target fluid. The affinity of the internal surfaces 31, 32 can be established in a variety of ways. For example, the affinity can be established by the material of the corresponding portion of the fluid channel 21. For example, a hydrophilic surface could be made of hydrogels, polyamides, or hydroxylated polyurethanes. As another example, a hydrophobic surface could be made of polytetrafluoroethylene or polymethylene. Alternatively, the affinity can be established by a treatment, such as a coating, applied to the interior of the fluid channel 21. Such treatments include plasma or corona treatments or coating a surface with hydrogels, polyamides, or hydroxylated polyurethanes (to create a hydrophilic surface) or coating a surface with polytetrafluoroethylene or polymethylene (to create a hydrophobic surface. For example, the affinity of each internal surface can be established by applying a first coating on the at least one first internal surface and applying a second coating to the at least one second internal surface. As a more specific example, the above substances can be applied in any suitable order, with appropriate masking (e.g., apply or coat a first coating on the first internal surface, mask the first coating, and apply or coat a second coating on the second internal surface).
As one example of the affinities of the surfaces for the fluids, the at least one first internal surface 31 can be configured to be one of oleophobic and hydrophobic and the at least one second internal surface 32 can be configured to be the other of oleophobic and hydrophobic. In a further example, the at least one first internal surface 31 can be configured to be one of hydrophilic and hydrophobic and the second internal surface can be configured to be the other of hydrophilic and hydrophobic 32. For example, for hydrophilicity a contact angle with water of no more than 50 degrees is preferred, and for hydrophobicity a contact angle with water of more than 110 degrees is preferred.
When multiple immiscible fluids flow in fluid channel 21, a fluid interface 38 is created by a carrier fluid and a target fluid. Depending on parameters, such as the configuration of the fluid channel 21, the flow rates, and the fluids used, the fluid interface may occur at different locations within the fluid channel 21. For example, the parameters may cause the fluid interface 38A to exist at the location in the fluid channel 21A shown in
In various embodiments, different internal surface portions of the fluid channel are each configured to have affinities to different fluids. For example, a first internal surface portion has an affinity to a carrier fluid (e.g., an aqueous fluid) and a second internal surface portion has an affinity to a target fluid (e.g., an oleic fluid). In some embodiments, the first internal surface portion has an affinity to an aqueous fluid and the second internal surface portion has an affinity to an oleic fluid. Because the carrier fluid and the target fluid are immiscible, the first internal surface portion and the second internal surface portion have different fluid affinities. Further, the first internal surface portion and the second internal surface portion are configured to substantially maintain stable fluid flow of the two immiscible fluids in the fluid channel.
As an example, in the embodiment shown in
In another example, stages and modules of system 10 may also be together in a single unit and fully implanted in the body of the patient. This arrangement is depicted in Example C of
Example B of
Positioning only the secondary exchange module within the patient's body results in a less traumatic and safer implantation as compared with positioning the entire system within the body. As compared with positioning the entire system outside of the body, this arrangement is safer because it decreases the movement and jostling of the blood which decreases the likelihood of bleed out and minimizes the risk of disconnecting the blood path. This also reduces the risk of infection since the connection to the vascular system is completely internal. Finally, in this arrangement, the blood does not cool as it travels to and from the system.
Referring now to
As shown in
Exchange module 712 transfers oxygen from gas 714 having oxygen therein to carrier fluid 716, and transfers the oxygen from oxygen loaded carrier fluid 716 to physiological fluid 718 to produce oxygen loaded physiological fluid 722. Simultaneously, carbon dioxide from physiological fluid 718 is transferred to the carrier fluid 716 and the carbon dioxide in carrier fluid 716 is transferred to gas 714 to create carbon dioxide loaded gas 724. The stream of carrier fluid 716, as a result of the continuous gas transfer, is an oxygen-enriched stream. For example, the stream may be 100% oxygen or may be a 40% oxygen/60% nitrogen stream. Carbon dioxide loaded gas is preferably expelled from exchange module 712. Oxygen loaded physiological fluid 722, which now has carbon dioxide removed, is transferred to vascular system of a patient 720.
As a result, system 710, through exchange module 712, receives physiological fluid 718 having carbon dioxide therein, effectively removes carbon dioxide therefrom and loads physiological fluid 718 with oxygen. Oxygen loaded physiological fluid 722 may be then transferred to vascular system of patient 720. Thus, system 710 can be used to effectively assist or replace the function of diseased or damaged lung(s). In one embodiment, system 710 may be used as an artificial lung.
A schematic diagram of an embodiment of system 710 is shown in
A cross-sectional view of the exchange chamber of exchange module 712 is shown in
As described above, the carrier fluid 716 and physiological fluid 718 are preferably immiscible, and accordingly, it is shown in
The exchange chamber of exchange module 712 is sized and dimensioned for the efficient flow of the fluids through the module. According to various embodiments, using the dimension indicators in
Despite the liquid channel being of small size, the system is tolerant of pulsatility. The system can be run using peristaltic pumps for both the physiologic fluid and the carrier fluid. It is not necessary that the two utilize the same peristaltic pump, or the same type of pump, each can be presented with different pulsatility profiles. The system has been tested with both fluids on pulsatile pump heads pulsing up to 50% of average pulsations, and the two fluids out of synch. The system is functional without pulsatility in the flow, using centrifugal or impeller pumps for long term flow or syringe pumps for short term flow.
Inside the chamber, where the physiological fluid and carrier fluid are in fluidic contact, they are at essentially the same pressure. The gas pressure in the chamber depends on the properties of the membrane 750 and to a lesser extent on the pressure of the carrier fluid. Some membranes 750 will allow discrete bubbles of gas to form if the gas pressure is too high relative to the liquid, or liquid to leak through if its pressure is too high relative to the gas, so the pressure needs to be adjusted accordingly. Accordingly, the most likely material for the membrane 750 is a silicone, which is less sensitive to these incursions and leaves the gas pressure largely independent of the pressure of the carrier fluid.
This application claims priority to U.S. Provisional Application No. 62/852,517, filed May 24, 2019, which is hereby incorporated by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
62852517 | May 2019 | US |